Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?
Author:
Open Access
- 2 April 2013
- journal article
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 2 (3) , 222-224; 228
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- PROGNOSTIC SIGNIFICANCE OF LYMPHOVASCULAR INVASION OF BLADDER CANCER TREATED WITH RADICAL CYSTECTOMYJournal of Urology, 2005
- Neoadjuvant Chemotherapy for Transitional Cell Carcinoma of the Bladder: A Systematic Review and Meta-AnalysisJournal of Urology, 2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysisThe Lancet, 2003
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000
- Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.1999
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.Journal of Clinical Oncology, 1990
- Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseCancer, 1989